Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.
How has the nuvaxovid market grown in recent years?
In recent years, the market size of nuvaxovid has seen a hike of XX (HCAGR). The market projection suggests that it will evolve from $XX million in 2024 to $XX million in 2025, equating to a compound annual growth rate (CAGR) of XX%. Factors contributing to this growth during the historical timeline were higher global rates of vaccination, an upsurge in regulatory approvals and research funding, heightened levels of infection, and a greater understanding of the advantages of vaccines.
How is the nuvaxovid market size expected to evolve during the forecast period?
Forecasted growth for the nuvaxovid market is projected to reach XX (FCAGR) in the years to come, ultimate rising to a value of $XX million by 2029 at a compounded annual growth rate (CAGR) of XX%. The predicted rise in the forecast period is ascribed to the mounting global need for COVID-19 vaccines, elevated investment in vaccine production capabilities, an increase in demand for immunizations related to travel, spur in earnings stimulating vaccine purchases, and surge in the usage of online portals for vaccine orders. Key augmenting trends during the forecast period involve advancements in vaccine distribution techniques, improvement in vaccine cold-chain logistics, collaborations with drug manufacturers for local distribution, progress in vaccine production technology, and developments in vaccine preservation technology.
Get your nuvaxovid market report here!
https://www.thebusinessresearchcompany.com/report/nuvaxovid-global-market-report
Which key drivers are propelling the nuvaxovid market’s growth?
The increase in infectious diseases is anticipated to propel the nuvaxovid market’s expansion. These diseases, which are caused by harmful microorganisms such as bacteria, viruses, fungi, or parasites, can spread from person to person or through environmental contact. Factors such as global travel, urbanization, climate change, antimicrobial resistance, and the appearance of new pathogens contribute to the escalating rates of infectious disease. Nuvaxovid plays a critical role in mitigating this issue by offering a potent vaccine to prevent COVID-19 and minimize its transmission, which aids in controlling the global spread of the virus. For instance, the Office for National Statistics, a government agency in the UK, reported an increase in COVID-19 infections in March 2023, with about 2.66% (1 in 40 people) of the population in England testing positive during the week ending 13 March 2023. Trends were unsure in Wales (2.41%, 1 in 40), Scotland (2.59%, 1 in 40), and Northern Ireland (1.42%, 1 in 70). Infection rates rose in the North West, East Midlands, and South East, impacting age ranges from 2 years to school Year 11 and those aged 50 and above. Hospital admissions for confirmed COVID-19 in England climbed to 10.62 per 100,000 people by the week ending 19 March 2023. The UK recorded 619 COVID-19-related deaths by the week ending 17 March 2023, an increase from 605 the previous week. Consequently, the growing incidence of infectious diseases is stimulating the nuvaxovid market.
What are the market segments in the nuvaxovid industry?
The nuvaxovid market covered in this report is segmented –
1) By Clinical Indication: Primary Immunization; Booster Immunization; Immunocompromised Patients; Elderly Population; Pediatric Immunization; Travel Immunization
2) By End Use: Hospitals; Clinics; Ambulatory Care; Home Care
3) By Distribution Channel: Retail Pharmacies; Online Sales; Government Programs
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20319&type=smp
Which leading companies are shaping the growth of the nuvaxovid market?
Major companies operating in the nuvaxovid market are Novavax Inc.
What key trends are currently impacting the nuvaxovid market’s development?
In the nuvaxovid market, the primary trend is the creation of innovative vaccination delivery systems, such as advanced versions of COVID-19 vaccines. This is aimed at providing a potent solution to prevent COVID-19 and tackling the rising variants, thus bolstering global immunization initiatives. An advanced version of the COVID-19 vaccine improves upon the original by enhancing protection against the new strains of the SARS-CoV-2 virus. This ensures its continued efficacy in mitigating severe sickness and hospitalization. In a notable example from October 2024, Novavax, Inc., a biotechnology firm based in the US, received marketing authorization from the European Commission for its updated 2024-2025 Nuvaxovid COVID-19 vaccine (recombinant, adjuvanted) for the prevention of COVID-19 in those aged 12 and above in the European Union. The updated vaccine targets the JN.1 lineage and offers cross-protection against several other variants. This approval plays a crucial role by widening access to the reformulated vaccine to address the upcoming COVID-19 variants and aiding in the consistent worldwide vaccination drive.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20319
Which geographic areas are influencing the growth of the nuvaxovid market?
North America was the largest region in the nuvaxovid market in 2024. The regions covered in the nuvaxovid market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
respiratory diseases drugs Global Market Report 2025
https://thebusinessresearchcompany.com/report/respiratory-disease-drugs-global-market-report
Global Pharmaceutical Drugs And Biologics Logistics Opportunities And Strategies Global Market Report 2025
https://thebusinessresearchcompany.com/report/pharmaceutical-drugs-and-biologics-logistics-market
Global Anesthesia And Respiratory Devices Opportunities And Strategies Global Market Report 2025
https://thebusinessresearchcompany.com/report/anesthesia-and-respiratory-devices-market
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on: